These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20884440)

  • 1. Vascular response to a third generation everolimus-eluting stent.
    Wilson GJ; Huibregtse BA; Stejskal EA; Crary J; Starzyk RM; Dawkins KD; Barry JJ
    EuroIntervention; 2010 Sep; 6(4):512-9. PubMed ID: 20884440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the SYNERGY with the PROMUS (XIENCE V) and bare metal and polymer-only Element control stents in porcine coronary arteries.
    Wilson GJ; Huibregtse BA; Pennington DE; Dawkins KD
    EuroIntervention; 2012 Jun; 8(2):250-7. PubMed ID: 22717928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xience V everolimus-eluting coronary stent.
    Kukreja N; Onuma Y; Serruys PW
    Expert Rev Med Devices; 2009 May; 6(3):219-29. PubMed ID: 19419279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent.
    Beijk MA; Piek JJ
    Expert Rev Med Devices; 2007 Jan; 4(1):11-21. PubMed ID: 17187467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental efficacy of an everolimus eluting cobalt chromium stent.
    Carter AJ; Brodeur A; Collingwood R; Ross S; Gibson L; Wang CA; Haller S; Coleman L; Virmani R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):97-103. PubMed ID: 16755598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strut tissue coverage and endothelial cell coverage: a comparison between bare metal stent platforms and platinum chromium stents with and without everolimus-eluting coating.
    Soucy NV; Feygin JM; Tunstall R; Casey MA; Pennington DE; Huibregtse BA; Barry JJ
    EuroIntervention; 2010 Nov; 6(5):630-7. PubMed ID: 21044918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System).
    Kereiakes DJ; Cutlip DE; Applegate RJ; Wang J; Yaqub M; Sood P; Su X; Su G; Farhat N; Rizvi A; Simonton CA; Sudhir K; Stone GW
    J Am Coll Cardiol; 2010 Dec; 56(25):2084-9. PubMed ID: 21144968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial.
    Applegate RJ; Hermiller JJ; Sanz M; Doostzadeh J; Pierson W; Su X; Lansky AJ; Sudhir K; Stone GW
    EuroIntervention; 2010 Sep; 6(4):437-46. PubMed ID: 20884430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status of the Xience V® everolimus-eluting coronary stent system.
    Claessen BE; Caixeta A; Henriques JP; Piek JJ
    Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1363-74. PubMed ID: 20936921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial.
    Stone GW; Teirstein PS; Meredith IT; Farah B; Dubois CL; Feldman RL; Dens J; Hagiwara N; Allocco DJ; Dawkins KD;
    J Am Coll Cardiol; 2011 Apr; 57(16):1700-8. PubMed ID: 21470815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus for stent-based intracoronary applications.
    Grube E; Buellesfeld L
    Rev Cardiovasc Med; 2004; 5 Suppl 2():S3-8. PubMed ID: 15184828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin analogs for stent-based local drug delivery. Everolimus- and tacrolimus-eluting stents.
    Grube E; Buellesfeld L
    Herz; 2004 Mar; 29(2):162-6. PubMed ID: 15054588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic sub-study in the SPIRIT III Randomized and Controlled Trial of XIENCE V everolimus eluting coronary stent system.
    Wang Q; Pierson W; Sood P; Bol C; Cannon L; Gordon P; Saucedo J; Sudhir K
    J Interv Cardiol; 2010 Feb; 23(1):26-32. PubMed ID: 20040005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PLATINUM QCA: a prospective, multicentre study assessing clinical, angiographic, and intravascular ultrasound outcomes with the novel platinum chromium thin-strut PROMUS Element everolimus-eluting stent in de novo coronary stenoses.
    Meredith IT; Whitbourn R; Scott D; El-Jack S; Zambahari R; Stone GW; Teirstein PS; Starzyk RM; Allocco DJ; Dawkins KD
    EuroIntervention; 2011 May; 7(1):84-90. PubMed ID: 21550907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study on provisional stenting with sirolimus-eluting stent vs. bare metal stent for the treatment of true coronary bifurcations: the PROSUMER (PROvisional with sirolimus-eluting vs. bare metal stents in truE bifuRcations) study.
    Tanzilli G; Pelliccia F; Pasceri V; Speciale G; Greco C; Arrivi A; Viceconte N; Mangieri E; Gaudio C
    Int J Cardiol; 2011 Jan; 146(2):240-1. PubMed ID: 21093942
    [No Abstract]   [Full Text] [Related]  

  • 19. Initial clinical experience with an everolimus eluting platinum chromium stent (Promus Element) in unselected patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Sarno G; Lagerqvist B; Carlsson J; Olivecrona G; Nilsson J; Calais F; Götberg M; Nilsson T; Sjögren I; James S
    Int J Cardiol; 2013 Jul; 167(1):146-50. PubMed ID: 22244480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents.
    Chieffo A; Foglieni C; Nodari RL; Briguori C; Sangiorgi G; Latib A; Montorfano M; Airoldi F; Michev I; Carlino M; Colombo A; Maseri A
    Am J Cardiol; 2009 Dec; 104(12):1660-7. PubMed ID: 19962471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.